AirSculpt Technologies Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de AirSculpt Technologies ont diminué à un taux annuel moyen de -36.4%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en à 4% par an. Les revenus ont augmenté de en à un taux moyen de 7.1% par an.
Informations clés
-36.40%
Taux de croissance des bénéfices
2.90%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 8.50% |
| Taux de croissance des recettes | 7.10% |
| Rendement des fonds propres | -11.19% |
| Marge nette | -7.39% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jun 26
AIRS: Raised Price View And 2026 Outlook Will Shape Fair Risk Balance
Analysts have raised their price target on AirSculpt Technologies stock from $3.00 to $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What’s in the News for AirSculpt Technologies AirSculpt Technologies affirmed revenue guidance for the full year 2026, with expectations of approximately US$151 million to US$157 million.Article d’analyse • Jan 06
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Share Price Is Still Matching Investor Opinion Despite 35% Slump
Unfortunately for some shareholders, the AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) share price has dived 35% in the...Seeking Alpha • Oct 29
AirSculpt Technologies: Upgrading To Buy On Improving Fundamentals
Summary Upgrade AirSculpt Technologies (AIRS) to 'Buy' as strong technical momentum and record lead generation drive optimism for further upside. AIRS delivered positive sequential growth in Q2, with improved gross margins, reduced SG&A expenses, and lower customer acquisition costs supporting profitability. Debt reduction and the highest operating cash flow in eight quarters position AIRS closer to sustained profitability, despite macro risks and elevated valuation. Q3 earnings are critical; AIRS must meet or exceed $39.8 million in revenue to maintain momentum and justify its premium sales multiple. Read the full article on Seeking AlphaArticle d’analyse • Oct 05
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Shares Climb 32% But Its Business Is Yet to Catch Up
Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...Article d’analyse • Sep 24
Estimating The Intrinsic Value Of AirSculpt Technologies, Inc. (NASDAQ:AIRS)
Key Insights AirSculpt Technologies' estimated fair value is US$7.56 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • Aug 29
Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jul 25
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 28% Share Price Surge Not Quite Adding Up
Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...Article d’analyse • Jun 10
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Shares Climb 69% But Its Business Is Yet to Catch Up
The AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) share price has done very well over the last month, posting an...Article d’analyse • Apr 25
Some Confidence Is Lacking In AirSculpt Technologies, Inc. (NASDAQ:AIRS) As Shares Slide 31%
To the annoyance of some shareholders, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares are down a considerable 31...Article d’analyse • Feb 25
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Share Price Matching Investor Opinion
It's not a stretch to say that AirSculpt Technologies, Inc.'s ( NASDAQ:AIRS ) price-to-sales (or "P/S") ratio of 1.4x...Article d’analyse • Jan 28
Investors Could Be Concerned With AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital
Ignoring the stock price of a company, what are the underlying trends that tell us a business is past the growth phase...Article d’analyse • Dec 04
An Intrinsic Calculation For AirSculpt Technologies, Inc. (NASDAQ:AIRS) Suggests It's 40% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, AirSculpt Technologies fair value estimate is US$12.46 Current...Article d’analyse • Nov 14
Why Investors Shouldn't Be Surprised By AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 30% Share Price Surge
Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...Article d’analyse • Nov 07
Is AirSculpt Technologies (NASDAQ:AIRS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Oct 20
The Return Trends At AirSculpt Technologies (NASDAQ:AIRS) Look Promising
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...Article d’analyse • Sep 28
Optimistic Investors Push AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares Up 29% But Growth Is Lacking
AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shareholders have had their patience rewarded with a 29% share price jump...Article d’analyse • Sep 25
Is It Time To Consider Buying AirSculpt Technologies, Inc. (NASDAQ:AIRS)?
AirSculpt Technologies, Inc. ( NASDAQ:AIRS ), might not be a large cap stock, but it saw a significant share price rise...Article d’analyse • Aug 01
The Market Lifts AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares 26% But It Can Do More
Those holding AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares would be relieved that the share price has rebounded...Article d’analyse • Apr 04
There's Been No Shortage Of Growth Recently For AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Article d’analyse • Feb 23
Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Article d’analyse • Dec 14
AirSculpt Technologies, Inc. (NASDAQ:AIRS) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shareholders are no doubt pleased to see that the share price has bounced...Article d’analyse • Nov 12
US$8.19: That's What Analysts Think AirSculpt Technologies, Inc. (NASDAQ:AIRS) Is Worth After Its Latest Results
There's been a notable change in appetite for AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares in the week since its...Article d’analyse • Sep 20
Be Wary Of AirSculpt Technologies (NASDAQ:AIRS) And Its Returns On Capital
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...Article d’analyse • Oct 29
Capital Allocation Trends At AirSculpt Technologies (NASDAQ:AIRS) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Seeking Alpha • Aug 27
AirSculpt Technologies: Niche Offering Offset By Profitability, Valuation
Summary AirSculpt Technologies presents with a unique offering with exposure to alternative medical sectors in cosmetics. The company's growth strategy is well received but comes with notable execution risks. Shares appear to be reasonably valued at current levels, however, deeper examination of financials places questions on just what we are buying. With these points in mind, we value AIRS a hold. Investment summary AirSculpt Technologies, Inc. (AIRS) has piqued our interest since listing back in FY21. It operates in a novel segment of 'body contouring procedures' and is best known for its AirSculpt procedure, under the subsidiary brand Elite Body Sculpture. The proprietary procedure is touted due to its minimally invasive nature that contrasts to traditional liposuction. Its growth strategy is to open new centres and expand/relocate existing ones, ultimately driving up revenue per case, cases per room and overall case numbers as part of its growth strategy. Exhibit 1. AIRS 6-month price action Data: Refinitiv Eikon Despite the allure, forensics over its financial statements reveal there to be a loose fit to the kind of equity premia we are seeking exposure to in H2 FY22. Valuations are supportive of a neutral view and regulatory headwinds in adjacent markets [Australia, to be specific] has us cautious on the ramifications for global peers. With these points in mind, we rate AIRS a hold. Q2 earnings indicate growth trends We see the differentiated strengths of AIRS' procedures in its most recent earnings, with upsides to consensus at the top and bottom lines. Forecasts on the global cosmetic market growth published in April 2022 predict a geometric growth of 3.6% per year from 2021 until 2028. Contrary evidence suggests a 9.6% CAGR into 2030. AIRS printed revenue of $49.7 million for the period, up 42% YoY. Presuming either of the above forecasts are true, then AIRS above top-line growth suggest it gained additional market share during the quarter. As a side note, however, this is a murky segment - recent controversies in the Australian cosmetic surgery market surrounding regulation are a potential risk for global participants. Cases also increased 22.5% YoY to 3,691 total cases, as seen in Exhibit 2. The company records each case as 1 visit, with doesn't factor in that each patient may have multiple treatment areas per visit. Nevertheless, it opened 4 new centres during Q2 FY21, bringing total centres to 19. Meanwhile, revenue per case increased 16% YoY to ~$13,450, supported by the company's access to 38 procedure rooms versus 25 the year prior. However, the 10-Q did note that cases per procedure room declined due to the addition of the 13 new centres and expansion of existing ones, versus an organic decline over the 12 months. There is good reason to estimate that trends will normalize as procedures per room level to overall company growth trends. Exhibit 2. Above-market growth statistics imply the company might be gaining additional market share Image: HB Insights, AIRS SEC Filings Despite the upsides in booked revenues for the quarter, our findings indicate there are drains and pulls on liquidity that may place stress on AIRS' current position. As seen below, we estimate there to be around 3-4 quarters of cash runway remaining with the company's most recent earnings. It needs a substantial growth in cash conversion from net income to bolster its position here and prevent additional dilutive equity raise(s) and/or expensive debt issuance/origination in the high yield debt capital markets. Noteworthy to this point, however, is the company declared a $0.41/share special dividend to be paid in September. Exhibit 3. Data: HB Insights Estimates The company also reports non-GAAP EBITDA and recorded a $1.01 million YoY increase to $15.2 million as seen in Exhibit 4. This is despite earnings narrowing by 94% YoY from ~$10 million to $583,000. According to the 10-Q, "management assesses and believes investors should assess our operating performance" [using non-GAAP EBITDA]. We take some issue with this recommendation. Firstly, the company booked ~$7.3 million in stock-based compensation ("SBC") for the period, and saw an interest expense of $1.5 million - each up substantially on the year. Moreover, as seen below, AIRS asks us to ignore the impact of new centre opening and relocation costs, plus the SBC, plus the loss on asset disposals. We argue these are expenses that must be realized in the analysis of free cash flow and valuation. We can't simply ignore that these 3 expenses in particular total to $9.3 million, and removing them from the equation, non-GAAP EBITDA is ~$5.9 million. Not to mention, it also recorded a $60 million payment to its parent organization. Therefore, whilst it converted $8.5 million in quarterly cash flow, this was more than offset by these expenditures. Exhibit 4. Non-GAAP EBITDA includes several expenditures that we argue should be included in cash flow analysis Data: AIRS 10-Q, Q2 FY2022 Valuation AIRS' growth strategy involves opening de novo centres, expanding existing ones and acquiring additional assets into its portfolio. In that regard, AIRS' corporate value stems from its popular set of procedures - particularly AirSculpt liposuction - as an intangible plus its tangible book value. Any value manager will also familiarize this information with cash flow multiples and forecasts.Seeking Alpha • Aug 12
AirSculpt Technologies reports Q2 earnings beat; reaffirms FY22 guidance
AirSculpt Technologies press release (NASDAQ:AIRS): Q2 GAAP EPS of $0.01 beats by $0.01. Revenue of $49.7M (+42.1% Y/Y) beats by $4.79M. Same-center cases and revenue per case for the second quarter of 2022 were up 4.7% and 15.0%, respectively, over the prior year period. For the second quarter of 2022, the company’s adjusted EBITDA grew 7.1% to $15.2M as compared to $14.2M for the prior year period. The company is reiterating its revenue outlook of $175-179 million vs. consensus of $177.40M and its Adjusted EBITDA guidance in the range of $58 - $60 million. The Company has opened two centers in 2022 and anticipates opening two additional centers in the second half of the year.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment AirSculpt Technologies gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 152 | -11 | 93 | 0 |
| 31 Dec 25 | 152 | -12 | 92 | 0 |
| 30 Sep 25 | 158 | -18 | 96 | 0 |
| 30 Jun 25 | 165 | -15 | 100 | 0 |
| 31 Mar 25 | 172 | -17 | 112 | 0 |
| 31 Dec 24 | 180 | -8 | 105 | 0 |
| 30 Sep 24 | 189 | -8 | 107 | 0 |
| 30 Jun 24 | 193 | -3 | 107 | 0 |
| 31 Mar 24 | 198 | 2 | 100 | 0 |
| 31 Dec 23 | 196 | -4 | 108 | 0 |
| 30 Sep 23 | 189 | -7 | 110 | 0 |
| 30 Jun 23 | 181 | -13 | 108 | 0 |
| 31 Mar 23 | 175 | -14 | 106 | 0 |
| 31 Dec 22 | 169 | -15 | 106 | 0 |
| 30 Sep 22 | 166 | -33 | 112 | 0 |
| 30 Jun 22 | 161 | -17 | 100 | 0 |
| 31 Mar 22 | 147 | -8 | 84 | 0 |
| 31 Dec 21 | 133 | 0 | 69 | 0 |
| 30 Sep 21 | 119 | 31 | 41 | 0 |
| 30 Jun 21 | 102 | 25 | 36 | 0 |
| 31 Mar 21 | 78 | 15 | 30 | 0 |
| 31 Dec 20 | 63 | 8 | 26 | 0 |
| 31 Dec 19 | 41 | -2 | 22 | 0 |
Des revenus de qualité: AIRS n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: AIRS n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AIRS n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 36.4% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de AIRS au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: AIRS n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Healthcare ( 15.3% ).
Rendement des fonds propres
ROE élevé: AIRS a un retour sur capitaux propres négatif ( -11.19% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 12:47 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
AirSculpt Technologies, Inc. est couverte par 6 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| Benjamin Mayo | Leerink Partners LLC |